
Alnylam Pharmaceuticals’ shares lost close to half of their value as it was forced to end a trial of its …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

